JP2015519402A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015519402A5 JP2015519402A5 JP2015517445A JP2015517445A JP2015519402A5 JP 2015519402 A5 JP2015519402 A5 JP 2015519402A5 JP 2015517445 A JP2015517445 A JP 2015517445A JP 2015517445 A JP2015517445 A JP 2015517445A JP 2015519402 A5 JP2015519402 A5 JP 2015519402A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- compound according
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 42
- 150000003839 salts Chemical class 0.000 claims 34
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 201000000980 schizophrenia Diseases 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261659911P | 2012-06-14 | 2012-06-14 | |
| US61/659,911 | 2012-06-14 | ||
| PCT/US2013/045768 WO2013188724A1 (en) | 2012-06-14 | 2013-06-14 | Azetidine and piperidine compounds useful as pde10 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015519402A JP2015519402A (ja) | 2015-07-09 |
| JP2015519402A5 true JP2015519402A5 (enExample) | 2016-07-28 |
Family
ID=48692687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015517445A Pending JP2015519402A (ja) | 2012-06-14 | 2013-06-14 | Ｐｄｅ１０阻害剤として有用なアゼチジンおよびピペリジン化合物 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US8691986B2 (enExample) |
| EP (1) | EP2864317A1 (enExample) |
| JP (1) | JP2015519402A (enExample) |
| KR (1) | KR20150023417A (enExample) |
| CN (1) | CN104619694A (enExample) |
| AP (1) | AP2014008136A0 (enExample) |
| AR (1) | AR091436A1 (enExample) |
| AU (1) | AU2013274153B2 (enExample) |
| BR (1) | BR112014031368A2 (enExample) |
| CA (1) | CA2875802A1 (enExample) |
| CL (1) | CL2014003391A1 (enExample) |
| CO (1) | CO7160011A2 (enExample) |
| CR (1) | CR20150012A (enExample) |
| EA (1) | EA201590014A1 (enExample) |
| HK (1) | HK1203935A1 (enExample) |
| IL (1) | IL235901A0 (enExample) |
| MA (1) | MA37748B1 (enExample) |
| MX (1) | MX2014014924A (enExample) |
| PE (1) | PE20150348A1 (enExample) |
| PH (1) | PH12014502780A1 (enExample) |
| SG (1) | SG11201408168UA (enExample) |
| TN (1) | TN2014000510A1 (enExample) |
| TW (1) | TWI508959B (enExample) |
| UY (1) | UY34858A (enExample) |
| WO (1) | WO2013188724A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012013130A (es) | 2010-05-13 | 2013-04-11 | Amgen Inc | Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10. |
| UY34858A (es) * | 2012-06-14 | 2013-11-29 | Amgen Inc | Compuestos de azetidina y piperidina útiles como inhibidores de pde10 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US8497265B2 (en) * | 2010-05-13 | 2013-07-30 | Amgen Inc. | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors |
| MX2012013130A (es) * | 2010-05-13 | 2013-04-11 | Amgen Inc | Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10. |
| MX2012013128A (es) * | 2010-05-13 | 2013-03-20 | Amgen Inc | Compuestos heterociclicos de nitrogeno como inhibidores de la fosfodiesterasa 10. |
| WO2011143366A1 (en) * | 2010-05-13 | 2011-11-17 | Amgen Inc. | Heteroaryloxycarbocyclyl compounds as pde10 inhibitors |
| UY34858A (es) * | 2012-06-14 | 2013-11-29 | Amgen Inc | Compuestos de azetidina y piperidina útiles como inhibidores de pde10 |
-
2013
- 2013-06-13 UY UY0001034858A patent/UY34858A/es not_active Application Discontinuation
- 2013-06-13 AR ARP130102085 patent/AR091436A1/es unknown
- 2013-06-14 HK HK15104351.8A patent/HK1203935A1/xx unknown
- 2013-06-14 US US13/917,699 patent/US8691986B2/en active Active
- 2013-06-14 SG SG11201408168UA patent/SG11201408168UA/en unknown
- 2013-06-14 CA CA2875802A patent/CA2875802A1/en not_active Abandoned
- 2013-06-14 JP JP2015517445A patent/JP2015519402A/ja active Pending
- 2013-06-14 EA EA201590014A patent/EA201590014A1/ru unknown
- 2013-06-14 KR KR1020147035700A patent/KR20150023417A/ko not_active Withdrawn
- 2013-06-14 MA MA37748A patent/MA37748B1/fr unknown
- 2013-06-14 AU AU2013274153A patent/AU2013274153B2/en not_active Expired - Fee Related
- 2013-06-14 BR BR112014031368A patent/BR112014031368A2/pt not_active IP Right Cessation
- 2013-06-14 MX MX2014014924A patent/MX2014014924A/es unknown
- 2013-06-14 EP EP13731237.7A patent/EP2864317A1/en not_active Withdrawn
- 2013-06-14 PE PE2014002438A patent/PE20150348A1/es not_active Application Discontinuation
- 2013-06-14 CN CN201380031076.4A patent/CN104619694A/zh active Pending
- 2013-06-14 AP AP2014008136A patent/AP2014008136A0/xx unknown
- 2013-06-14 WO PCT/US2013/045768 patent/WO2013188724A1/en not_active Ceased
- 2013-06-14 TW TW102121229A patent/TWI508959B/zh not_active IP Right Cessation
-
2014
- 2014-01-31 US US14/170,146 patent/US9303028B2/en active Active
- 2014-11-25 IL IL235901A patent/IL235901A0/en not_active IP Right Cessation
- 2014-12-04 TN TN2014000510A patent/TN2014000510A1/fr unknown
- 2014-12-11 PH PH12014502780A patent/PH12014502780A1/en unknown
- 2014-12-12 CL CL2014003391A patent/CL2014003391A1/es unknown
-
2015
- 2015-01-08 CO CO15003862A patent/CO7160011A2/es unknown
- 2015-01-13 CR CR20150012A patent/CR20150012A/es unknown
-
2016
- 2016-03-01 US US15/058,023 patent/US9493459B2/en active Active